A Direct Comparison of Immunological and Clinical Effects of Interleukin 2 with and without Interferon- in Humans1

Cancer Research

Volumn 53, Issue 6, 1993, Pages 1286-1292

  Schiller, Joan H ^a   Hank, Jacquoline ^a   Storer, Barry ^a   Bordiert, Agnes A ^a   Huseby Moore, Karen ^a   Albertini, Mark ^a   Bechhofer, Robin ^a   Wesley, Osvaldo ^a   Brown, Raymond R ^a   Bastn, Ann Mrowca ^a   Sondel, Paul M ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ALPHA INTERFERON; RECOMBINANT INTERLEUKIN 2;

ADULT; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; DOSE RESPONSE; DRUG ACTIVITY; DRUG POTENTIATION; DRUG THERAPY; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MALAISE; MALE; NATURAL KILLER CELL; PERFORMANCE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RIGOR; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; ANTIGENS, SURFACE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BETA 2-MICROGLOBULIN; COMPARATIVE STUDY; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMAN; INTERFERON ALFA-2A; INTERLEUKIN-2; LYMPHOCYTES; MALE; MIDDLE AGE; MONOCYTES; NEOPLASMS; RECEPTORS, INTERLEUKIN-2; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0027450783     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Foon, K. A. Biological response modifiers: the new immunotherapy. Cancer Res. 49: 1621-1639, 1989.
2. Borden, E. and Sondel, P. Lymphokines and cytokines as cancer treatment: immunotherapy realized. Cancer (Phila.), 65: 800-814, 1990.
3. Rosenberg, S. A. The immunotherapy and gene therapy of cancer. J. Clin. Oncol. 10: 180-199. 1992.
4. Finke, J. Lewis, I. and Ulchaker, J. Combination of IL-2 and IFNaA/D: antitumor and immunomodulatory activity. Lymphokine Res. 6: 1511, 1987.
5. Kim, B. Warnaka, R. and Imbembo, A. Interleukin-2 and alpha interferon therapy of advanced pulmonary metastases. Eur. Surg. Res. 21: 260-266, 1989.
6. Chikkala, N. F. Lewis, I. Ulchaker, J. et al: Interactive effects of alpha-interferon A/D and interleukin-2 on murine lymphokine-activated killer activity: analysis at the effector and precursor level. Cancer Res. 50: 1176-1182, 1990.
7. Cameron, B. R. Mcintosh, J. K. and Rosenberg, S. A. Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid a/pfai-interferon in the treatment of established murine hepatic metastases. Cancer Res. 48: 5810-5817, 1988.
8. Brunda, M. J. Bellantoni, D. and Sulich, V. In vivo anti-tumor activity of combinations of interferon alpha and interleukin-2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells. Int. J. Cancer, 40: 365-371, 1987.
9. Rosenberg, S. A. Schwarz, S. L. and Spiess, R J. Combination immunotherapy for cancer synergistic antitumor interactions of interleukin-2, alpha interferon, and tumor-infiltrating lymphocytes. J. Natl. Cancer Inst. 80: 1393-1397, 1988.
10. ligo, M, Sakurai, M. Tamura, T. et al. In vivo antitumor activity of multiple injections of recombinant interleukin 2, alone and in combination with three different types of recombinant interferon, on various syngeneic murine tumors. Cancer Res. 48: 260-264, 1988.
11. Weber, J. S. and Rosenberg, S. A. Modulation of murine tumor major histocompat-iblity antigens by cytokines in vivo and in vitro. Cancer Res. 48: 5818-5824, 1988.
12. Weber, J. S. Jay, G. Tanaka, K. and Rosenberg, S. A. Immunotherapy of a murine tumor with interleukin 2: increased sensitivity after MHC class 1 gene transfection. J. Exp. Med. 166: 1716-1733, 1987.
13. Yamaski, T. Kikuchi, H. Yamashita, J. et al. Immunoregulatory effects of interleukin 2 and interferon on syngeneic murine malignant glioma-specific cytotoxic T-lympho-cytes. Cancer Res. 48: 2981-2987. 1988.
14. Kuribayaski, K. Gillis, S. Kern. D. E. et al. Murine NK cell cultures: effects of interleukin-2 and interferon on cell growth and cytotoxic reactivity. J. Immunol. 126: 2321-2327, 1981.
15. Ochoa, A. C. Gromo, G. Alter, B. J. et al. Long-term growth of lymphokine-activated killer (LAK) cells: role of anti-CD3, beta-lL 1, interferon-a/p/uz and -beta. J. Immunol. 138: 2728-2733. 1987.
16. Hoher. W. Goldman, C. K. Casabo, L. et al. Expression of functional IL 2 receptors by lipopolysaccharide and interferon-gamma stimulated human monocytes. J. Immunol. 136: 2171-2175, 1986.
17. Hersey, P. MacDonald, M. Hall, C. et al. Immunological effects of recombinant interferon alpha-la. in patients with disseminated melanoma. Cancer (Phila.), 57: 1666-1675, 1986.
18. Lotze, M. T. Matory, Y. L. Ettinghausen, S. E. Rayner, A. A. Sharrow, S. O. Seipp, C. A. Custer, M. C. and Rosenberg, S. A. In vivo administration of purified Inter-leuken 2: II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL-2. J. Immunol. 135: 2865-2875, 1985.
19. Greiner, J. W. Guadagni, F. Noguchi, P. et al. Recombinant interferon enhances monoclonal antibody-targeting of carcinoma lesions in vivo. Science (Washington DC), 235: 895-898, 1987.
20. Rosenberg, S. A. Lotze, M. T. Yang, J. C. et al. Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J. Clin. Oncol. 7: 1863-1874, 1989.
21. Mittelman, A. Huberman, M. Puccio, C. et al. A phase I study of recombinant human interleukin-2 and alpha-interferon-2a in patients with renal cell cancer, colorectal cancer, and malignant melanoma. Cancer (Phila.), 66: 664-669, 1990.
22. Sznol, M. Mier, J. W. Sparano, J. et al. A phase I study of high-dose interleukin-2 in combination with interferon-alpha-2b. J. Biol. Response Modif. 9:529-537,1990.
23. Bukowski, R. M. Murthy, S. Sergi. J. et al. Phase I trail of continuous infusion recombinant interleukin-2 and intermittent recombinant interferon-alpha-2a: clinical effects. J. Biol. Response Modif. 9: 538-545. 1990.
24. Figlin, R. A. Belldegrun, A. Moldawer, N. et al. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2A: an active outpatient regimen in metastatic renal cell carcinoma. J. Clin. Oncol. 10: 414-421, 1992.
25. Budd, G. T. Osgood, B. Bama, B. et al. Phase I clinical trial of interleukin 2 and a-interferon: toxicity and immunologic effects. Cancer Res. 49: 6432-6436, 1989.
26. Budd, G. T. Murphy, S. Finke, J. et al. Phase I trial of high dose bolus interleukin-2 and interferon alpha-2 in patients wth metastatic melanoma. J. Clin. Oncol. 10: 804-809, 1992.
27. Sznol, M. Clark, J. W. Smith, J. W. Steis, R. G. Urba, W. J. Rubinstein, L. V. VanderMolen, L. A. Janik, J. Sharfman, W. H. Fenton, R. G. Creekmore. S. P. Kremers, P. Conlon, K. Hursey, J. Beveridge, J. and Longo, D. L. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alpha-2a in patients with metastatic melanoma and renal cell carcinoma. J. Natl. Cancer Inst. 84: 929-937, 1992.
28. Ilson, D. H. Motzer, R. J. Kradin, R. L. Vogelzang. N. J. Bajorin, D. F. Scher, H. I. Nanus, D. O'Moore, P. Marathias, K. and Bosl, G. J. A phase II trial of interleuken-2 and interferon alpha-la in patients with advanced renal cell carcinoma. J. Clin. Oncol. 10: 1124-1130, 1992.
29. Tamura, T. Sasaki, Y, Shinkai, T. et al. Phase I study of combination therapy with interleukin 2 and beta-interferon in patients with advanced malignancy. Cancer Res. 49: 730-735, 1989.
30. Krigel, R. L. Padavic-Shaller, K. A. Rudolph, A. R. Litwin, S. Konrad, M. Bradley, E. C. and Comis, R. L. A phase I study of recombinant interleukin 2 plus recombinant ß-interferon. Cancer Res. 48: 3875-3881, 1988.
31. Paolozzi, F. Zamkoff, K. Doyle, M. et al. Phase I trial of recombinant interleukin-2 and recombinant befa-interferon in refractory neoplastic diseases. J. Biol. Response Modif. 8: 122-139, 1989.
32. Baars, J. W. Wagstaff, J. Boven, E. et al. Phase I study on the sequential administration of recombinant human interferon-gamma and recombinant human interleukin-2 in patients with metastatic solid tumors. J. Natl. Cancer Inst. 83: 1408-1410, 1991.
33. Liao, S. Meranda, C. Auner, B. et al. Antibody-dependent cellular cytotoxicity (ADCC) of a mouse-human chimeric monoclonal antibody of the human IgGl subclass with specificity for human adenocarcinomas. Cancer Immunol. Immunother. 28: 77-86, 1989.
34. de la Maza, L. M. and Peterson, E. M. Dependence of the in vitro antiproliferative activity of recombinant human y-interferon on the concentration of tryptophan in culture media. Cancer Res. 48: 346-350, 1988.
35. Sosman, J. A. Kohler, P. C. Hank, J. et al. Repetitive weekly cycles of recombinant human interleukin-2: responses of renal cell carcinoma with acceptable toxicity. J. Nad. Cancer Inst, 80: 60-63, 1988.
36. Sosman, J. A. Kohler, P. C. Hank, J. et al. Repetitive weekly cycles of interleukin-2. II. Clinical and immunological effects of dose, schedule, and addition of indometha-cin. J. Nad. Cancer Inst. 80: 1451-1461, 1988.
37. Greiner, J. W. Guadagni, F. Goldstein, D. Smalley, R. V. Borden, E. C. Simpson, J. F. Molinolo, A. and Schlam, J. Intraperitoneal administration of interferon-gamma to carcinoma patients enhances expression of tumor-associated glycoprotein-72 and carcinoembryonic antigen on malignant ascites cells. J. Clin. Oncol. 10: 735-746, 1992.
38. West, W. H. Tauer, K. W. Yannelli, J. R. et al. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N. Engl. J. Med. 316: 898-905, 1987.
39. Clark, J. W. Smith, J. W. Steis, R. G. et al. Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen. Cancer Res. 50: 7343-7350, 1990.
40. Simmons, J. R. Buzdar, A. U. Ota, D. M. Marts, K. and Hortobagyi, G. N. Complications associated with indwelling catheters. Med. Pediatr. Oncol. 20: 22-25, 1992.
41. Carrington, B. M. Thomas, N. B. and Johnson, R. J. Selective splenic arteriography for interleukin-2 administration: radiologic complications from the initial 113 procedures. Eur J. Radiol. 14: 13-17, 1992.
42. Lokich, J. J. Bothe, A. Jr. Benotti, P. and Moore, C. Complications and management of implanted venous access catheters. J. Clin. Oncol. 3: 710-717, 1985.
43. Aronson, F. R. Libby, P. Brandon, E. P. Janicka, M. W. and Mier, J. IL-2 rapidly induces natural killer cell adhesion to human endothelial cells: a potential mechanism for endothelial injury. J. Immunol. 141: 158-163, 1988.
44. Siegel, J. P. and Puri, R. K. Interleukin-2 toxicity. J. Clin. Oncol. 9: 694-704, 1991.
45. Darbyshire, P. J. Weightman, N. C. and Speller, D. C. E. Problems associated with indwelling central venous catheters. Arch. Dis. Child. 60: 129-134, 1985.